# A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults

> **NCT02777554** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 144 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Apremilast IR
- **DRUG:** Apremilast XL

## Key facts

- **NCT ID:** NCT02777554
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-17
- **Primary completion:** 2016-11-22
- **Final completion:** 2016-11-22
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777554, "A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02777554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*